Radiation therapy plays a critical role in the management of breast cancer and the sensitivity of the tumor cells to radiation is a critical determinant of the probability of local control and, ultimately, of cure. Tumors fail locally after radiation therapy due to alterations in the molecular pathways associated with the particular tumor. A variety of molecular factors are being used in clinical practice to predict the prognosis and response to radiation therapy of breast cancer patients. Unraveling the underlying mechanism controlling the development of resistance to radiation therapy can help delay onset or eliminate development of resistance and prolong treatment efficacy. HuR is an RNA binding protein, which functions to increase or decrease mRNA stability. Altering the subcellular distribution or expression of RNA binding proteins that alter mRNA stability has the potential to significantly alter levels of key growth promoting proteins. In this grant application we are proposing to test if cytoplasmic accumulation of the RNA binding protein-HuR in human breast cancer cells is a mechanism for the origin of radioresistant breast cancers. We believe that cytoplasmic HuR, through its interaction with stress activated signaling pathways and DNA repair proteins, functions to stabilize transcripts essential for cell survival and plays an important role in dictating radiation response. To address this, we propose the following specific aims:
Aim 1 : Investigate HuR expression levels in a panel of breast tumor and normal cell lines and study the effect of radiation on the subcellular distribution of HuR. Test the hypothesis that cytoplasmic HuR effects the MAPK and DNA repair proteins to modulate radiation resistance.
Aim 2 : Conduct in vitro and in vivo studies using HuR-targeted siRNA and determine the consequences of therapeutic intervention on modulation of radiation response and DNA repair.
Aim 3 : Generation of tissue arrays and immunohistochemical analysis on a cohort of human breast carcinomas to look for possible associations between radiation response and HuR expression and other clinicopathologic variables.

Public Health Relevance

We hypothesize that a better understanding of the interactions between HuR, MAPK and DNA repair pathways will identify proteins responsible for sensitivity and resistance to ionizing radiation. Understanding these mechanisms will ultimately permit the optimal integration of new inhibitors into breast cancer therapy and ultimately overcome resistance and failure to radiation therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-02
Application #
8539819
Study Section
Special Emphasis Panel (ZRR1-RI-4)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$208,550
Indirect Cost
$67,639
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113
Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143
Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934
Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74
Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384

Showing the most recent 10 out of 68 publications